PrismRA testing, which takes genetic data into account, helps determine the most effective treatment for patients with rheumatoid arthritis. This was reported by MedicalXpress.
Rheumatoid arthritis is a disease in which a person’s immune system attacks the joints, causing severe pain. Treatment usually begins with long-term medications that reduce inflammation, such as methotrexate. If they are not effective, patients are prescribed new generation drugs. One of these is Humira (adalimumab). However, approximately half of the patients cannot benefit from this expensive drug, which has many side effects.
To assess which patients with rheumatoid arthritis are most likely to benefit from Humira (or its equivalents), scientists at Scipher Medicine developed the PrismRA test. It takes into account the patient’s genetic and other data, as well as blood tests.
PrismRA testing will help many patients quickly find effective medications for rheumatoid arthritis and save money. Choosing treatment appropriate to the genetics of the patient’s tumor has become a routine practice in oncology.
Previous scientists to create plant extract to normalize vascular function.